Yesterday, Vicore Pharma hosted a Covid-19 KOL seminar and shared the design for its upcoming pivotal phase III trial in the indication. Furthermore, the company participated in Redeye’s Orphan Drug seminar. While a significant trigger on its own, we also find it positive that the upcoming Covid-19 trial will increase the data package and understanding of C21 in general.